Boehringer’s Obesity Drug Achieves 16.6% Weight Loss in Trial; Further Data Pending

Boehringer Ingelheim has announced promising results for its experimental obesity treatment, showing a 16.6% reduction in body weight among participants in a late-stage clinical trial. The drug, developed in partnership with Zealand Pharma, targets both GLP-1 and GIP receptors, a mechanism similar to some of the most effective weight-loss medications currently on the market.

While the results are encouraging, the company emphasized that additional data is still needed before it can proceed with regulatory submissions. The full dataset, including long-term safety and efficacy outcomes, is expected to be presented at an upcoming medical conference.

The drug’s performance places it among the top contenders in the rapidly expanding obesity treatment market, which has seen significant growth following the success of GLP-1 receptor agonists like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.

Recent Developments in the Biotech Sector

Novartis Reports Q1 Decline Amid Generic Competition

Novartis shares dipped in early trading after the company disclosed a drop in first-quarter sales and operating profit. The decline was largely attributed to generic competition impacting key drugs, particularly Entresto, a heart failure medication. Despite the challenges, Novartis reaffirmed its full-year guidance, projecting low single-digit sales growth and a slight decline in core operating profit.

FDA Moves to Withdraw Amgen’s Tavneos Over Efficacy Concerns

The U.S. Food and Drug Administration (FDA) has taken steps to withdraw approval for Amgen’s Tavneos, a rare-disease drug approved in 2021. The agency cited new evidence indicating the drug is ineffective and that the original application contained “untrue statements of material fact.” Amgen has refused to voluntarily withdraw Tavneos, asserting that the drug remains safe for patients.

Eli Lilly Expands Gene Editing Portfolio with Profluent Partnership

Eli Lilly has entered into a collaborative agreement with Profluent, an AI-driven biotech company, to develop next-generation gene editors. The partnership aims to create gene-editing tools capable of inserting entire genes into patients, potentially offering new therapeutic avenues for genetic disorders. Financial terms of the deal were not disclosed.